Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: The role of adjuvant chemotherapy (ACT) for soft tissue sarcomas (STS) is not standard practice. We investigated effectiveness and tolerability of ACT in patients (pts) with operated high-risk STS in clinical practice. Methods: Medical records of pts with localized STS referred to Istituto Oncologico Veneto, Padova, from January 1, 2003 to July 07, 2012 were reviewed. Data were collected for pts with high-risk STS (size ≥5 cm, high grade and stage III). For those who received ACT, regimens used, drug doses, number of cycles, toxicity, and reasons for dose reduction or treatment interruption were recorded. Disease-free survival (DFS) and overall survival (OS) were calculated with the Kaplan–Meier method. Results: Out of 96 eligible pts, median age 62 years, 36 received ACT after loco-regional treatment. Median DFS was 29.6 months (95 % CI 13.2–46.0) in pts receiving ACT and 7.8 months (95 % CI 3.9–11.7) in untreated pts (p 

Original languageEnglish
Pages (from-to)679-685
Number of pages7
JournalJournal of Cancer Research and Clinical Oncology
Volume142
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Keywords

  • Adjuvant
  • Chemotherapy
  • Epirubicin
  • High risk
  • Ifosfamide
  • Sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience'. Together they form a unique fingerprint.

Cite this